Lamifin 125 DT Tablet contains Terbinafine 125 mg, an antifungal agent belonging to the allylamine class, indicated for the treatment of various superficial fungal infections. Terbinafine acts by inhibiting the enzyme squalene epoxidase, a key component in the biosynthesis of ergosterol, an essential sterol in fungal cell membranes. This inhibition results in the accumulation of squalene, which is toxic to fungal cells, leading to cell death. Lamifin 125 DT is primarily prescribed for dermatophytoses such as tinea corporis, tinea cruris, tinea pedis, and onychomycosis caused by susceptible strains of dermatophytes. The tablet is designed as a dispersible formulation to facilitate ease of administration, especially in patients with swallowing difficulties. Lamifin 125 DT should be used as directed by a healthcare professional, typically once daily, with the duration of therapy depending on the type and severity of the infection. Common adverse effects may include gastrointestinal disturbances, headache, and rash, while rare but serious effects include hepatotoxicity and allergic reactions. Liver function tests are recommended prior to and during prolonged therapy. Contraindications include hypersensitivity to terbinafine or any tablet components. Patient adherence to the full course of treatment is essential to prevent recurrence and resistance.